Is it possible to develop cancer vaccines to neoantigens, what are the major challenges, and how can these be overcome? Targeting the right antigens in the right patients

May 4, 2022 Nature.

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs

Eschweiler S, Ramírez-Suástegui C, Li Y, King E, Chudley L, Thomas J, Wood O, von Witzleben A, Jeffrey D, McCann K, Simon H, Mondal M, Wang A, Dicker M, Lopez-Guadamillas E, Chou TF, Dobbs NA, Essame L, Acton G, Kelly F, Halbert G, Sacco JJ, Schache AG, Shaw R, McCaul JA, Paterson C, Davies JH, Brennan PA, Singh RP, Loadman PM, Wilson W, Hackshaw A, Seumois G, Okkenhaug K, Thomas GJ, Jones TM, Ay F, Friberg G, Kronenberg M, Vanhaesebroeck B, Vijayanand P, Ottensmeier CH.

Feb 25, 2022 Science Immunology

Single-cell eQTL analysis of activated T cell subsets reveals activation and cell type–dependent effects of disease-risk variants

Benjamin J. Schmiedel,vCristian Gonzalez-Colin, Vicente Fajardo, Job Rocha, Ariel Madrigal, Ciro Ramirez-Suastegui, Sourya Bhattacharyya, Hayley Simon, Jason A. Greenbaum, Bjoern Peters, Gregory Seumois, Ferhat Ay, Vivek Chandra, Pandurangan, Vijayanand

Jan 14, 2022 Blood.

A congenital anemia reveals distinct targeting mechanisms for master transcription factor GATA1.

Ludwig L, Lareau CA, Bao EL, Liu N, Utsugisawa T, Tseng AM, Myers SA, Verboon JM, Ulirsch JC, Luo W, Muus C, Fiorini C, Olive ME, Vockley CM, Munschauer M, Hunter A, Ogura H, Yamamoto T, Inada H, Nakagawa S, Ozono S, Subramanian V, Chiarle R, Glader B, Carr SA, Aryee MJ, Kundaje A, Orkin S, Regev A, McCavit T, Kanno H, Sankaran VG.